AU2008322437B2 - Use of nitrite salts in chronic ischemia - Google Patents

Use of nitrite salts in chronic ischemia Download PDF

Info

Publication number
AU2008322437B2
AU2008322437B2 AU2008322437A AU2008322437A AU2008322437B2 AU 2008322437 B2 AU2008322437 B2 AU 2008322437B2 AU 2008322437 A AU2008322437 A AU 2008322437A AU 2008322437 A AU2008322437 A AU 2008322437A AU 2008322437 B2 AU2008322437 B2 AU 2008322437B2
Authority
AU
Australia
Prior art keywords
tissue
nitrite
ischemic
chronic
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008322437A
Other languages
English (en)
Other versions
AU2008322437A1 (en
Inventor
Christopher Kevil
David Lefer
Rakesh Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Louisiana State University
Original Assignee
UAB Research Foundation
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, Louisiana State University filed Critical UAB Research Foundation
Publication of AU2008322437A1 publication Critical patent/AU2008322437A1/en
Assigned to THE UAB RESEARCH FOUNDATION, LOUISIANA STATE UNIVERSITY reassignment THE UAB RESEARCH FOUNDATION Amend patent request/document other than specification (104) Assignors: BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA, LOUISIANA STATE UNIVERSITY, The UAB Research Foundation\
Application granted granted Critical
Publication of AU2008322437B2 publication Critical patent/AU2008322437B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008322437A 2007-11-15 2008-11-17 Use of nitrite salts in chronic ischemia Ceased AU2008322437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US315007P 2007-11-15 2007-11-15
US61/003,150 2007-11-15
PCT/US2008/083830 WO2009065142A2 (en) 2007-11-15 2008-11-17 Use of nitrite salts in chronic ischemia

Publications (2)

Publication Number Publication Date
AU2008322437A1 AU2008322437A1 (en) 2009-05-22
AU2008322437B2 true AU2008322437B2 (en) 2013-11-07

Family

ID=40639493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008322437A Ceased AU2008322437B2 (en) 2007-11-15 2008-11-17 Use of nitrite salts in chronic ischemia

Country Status (7)

Country Link
US (2) US9649334B2 (enExample)
EP (1) EP2219657A4 (enExample)
JP (2) JP5795165B2 (enExample)
CN (1) CN101939014B (enExample)
AU (1) AU2008322437B2 (enExample)
IL (1) IL205720A (enExample)
WO (1) WO2009065142A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US10463689B2 (en) 2009-10-14 2019-11-05 Board Of Supervisors Of Louisiana State University Pharmaceutical formulations of nitrite and uses thereof
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
EP4400101A1 (en) 2016-01-27 2024-07-17 SYK Technologies, LLC Nitric oxide topical application apparatus and methods
TWI698241B (zh) 2017-09-05 2020-07-11 國立成功大學 用於治療缺血的肝素組合物
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182815A1 (en) * 2004-07-09 2006-08-17 Use of nitrite salts for the treatment of cardiovascular conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
EP1105146A1 (en) 1998-07-14 2001-06-13 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
NZ513037A (en) 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
AU2001278197A1 (en) * 2000-07-28 2002-02-13 Bioenergy Inc. Compositions and methods for improving cardiovascular function
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
WO2003051341A1 (en) 2001-12-18 2003-06-26 Alza Corporation Dosage form for providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
CA2537222A1 (en) * 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2005018561A2 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
WO2006128032A2 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
NZ570704A (en) 2006-02-10 2011-09-30 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) * 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) * 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
JP2010519336A (ja) 2007-02-26 2010-06-03 ルンドベルク，ヨン 亜硝酸塩及び硝酸塩及びこれらを含む組成物の新規使用
HUE031982T2 (en) * 2007-02-26 2017-08-28 Heartbeet Ltd Performance enhancing composition and use thereof
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
EP2237788A4 (en) 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US10463689B2 (en) 2009-10-14 2019-11-05 Board Of Supervisors Of Louisiana State University Pharmaceutical formulations of nitrite and uses thereof
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182815A1 (en) * 2004-07-09 2006-08-17 Use of nitrite salts for the treatment of cardiovascular conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jung, KH et al (2006) Stroke. Volume 37. Pages 27442750 *

Also Published As

Publication number Publication date
JP2014139255A (ja) 2014-07-31
JP2011503212A (ja) 2011-01-27
IL205720A0 (en) 2010-11-30
US20110311653A1 (en) 2011-12-22
JP5908527B2 (ja) 2016-04-26
CN101939014A (zh) 2011-01-05
EP2219657A2 (en) 2010-08-25
JP5795165B2 (ja) 2015-10-14
AU2008322437A1 (en) 2009-05-22
IL205720A (en) 2015-08-31
US20170312310A1 (en) 2017-11-02
US9649334B2 (en) 2017-05-16
WO2009065142A2 (en) 2009-05-22
US10864229B2 (en) 2020-12-15
CN101939014B (zh) 2016-04-27
EP2219657A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
US10864229B2 (en) Use of nitrite salts in chronic ischemia
Koneru et al. Sildenafil‐mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin‐1
US10925890B2 (en) Use of dextran sulfate
US10596188B2 (en) Use of nitrite salts in treating tissue damage
JP2014533697A (ja) デフェリプロンを用いた処置方法
Oh et al. Effects of remote ischemic preconditioning on regional cerebral oxygen saturation in patients in the beach chair position during shoulder surgery: a double-blind randomized controlled trial
EP3375450A1 (en) Composition for treating apoplexy through nasal administration
WO2011038298A1 (en) Use of dipyridamole in chronic ischemia
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
HK1152657B (en) Use of nitrite salts in chronic ischemia
HK1152657A (en) Use of nitrite salts in chronic ischemia
Muir et al. Linagliptin Modulation of Inflammation in Chronic Coronary Artery Disease
SOLIMAN et al. Comparison of hemodynamic variables during continuous spinal anesthesia and general anesthesia in high risk cardiac patients: A randomized study
JP2025516717A (ja) 血管新生を誘発する薬剤
WO2025056188A1 (en) Relaxin medication
Fish The role of angiotensin II on vascular hypertrophy in genetic and renovascular hypertension
Niroomand Supernormal conduction mimicking a supraventricular capture beat during wide complex tachycardia
Chen Articles in PresS. Am J Physiol Regul Integr Comp Physiol (May 30, 2012). doi: 10.1152/ajpregu. 00114.2012

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired